Comparison of an automated thermodynamic treatment system (LipiFlow Â®) and eyelid warm compress for the treatment of meibomian gland dysfunction

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20170905001

Enrollment

Unknown

Registered

2017-09-05

Start date

2015-01-08

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

moderate severity of meibomian gland dysfunction (MGD). Meibomian gland dysfunction&#44

Interventions

the patients were instructed to use a hand towel or face cloth soaked with hot water&#44

excess water was wrung out and then&#44

the warm towel or cloth was placed over the skin of closed eyelids of the control eye with gentle pressure for 5 minutes.,The LipiFlowÂ® device applied heat (42.5Âº C) to upper and lower inner eyelid

whereas&#44

pulsatiling pressure was simultaneously applied to the outer eyelids using an inflatable air bladder 12. This device was capable of melting the meibomian gland contents without thermal injury and evac

Active Comparator Procedure/Surgery,Active Comparator Device

eyelid warm compress ,LipiFlow Â® Treatment

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: patients at least 18 years of age who had moderate severity of meibomian gland obstruction, defined as a Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire scores of 6-12 or lipid layer thickness (LLT) scores of 40-70 ICU (Interferometric Color Units), measured by using LipiViewÂ® (TearScience Inc., Morrisville, NC) or a meibomian gland score of 0-2 from MeibographyÂ® (Oculus, Wetzlar, Germany) or the number of expressible meibomian glands (EMG) yielding secretion of 3-6 glands of the lower eyelid.

Exclusion criteria

Exclusion criteria: patients with systemic diseases resulting in dry eyes such as systemic lupus erythematosus, rheumatoid arthritis, allergic diseases, etc., patients who had eyelid abnormalities, previous ocular surgery or trauma, and patients who used systemic medication affecting dry eyes such as antihistamines, tetracycline derivatives, isotretinoin and topical cyclosporine A or steroid within 1 month.

Design outcomes

Primary

Measure	Time frame
To evaluate the efficacy of a single thermal pulsation system treatment (LipiFlow Â®) compared with 1 year and 6 months total SPEED scores, LipiViewÂ®	—

Secondary

Measure	Time frame
Knowledge in management of vaginal pessary 2 weeks questionnaire	—

Countries

Thailand

Contacts

Public ContactWipawee Booranapong

Mahidol University

si93wbr@gmail.com024198037

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026